10-Q: Endo Inc. Reports Second Quarter 2024 Results Following Chapter 11 Emergence

Endo Inc. released its second quarter 2024 financial results, marking its first reporting period as a reorganized entity after emerging from Chapter 11 bankruptcy.

Summary

• Endo Inc. has released its financial results for the second quarter of 2024, which includes the period from April 23, 2024, when the company emerged from Chapter 11 bankruptcy, through June 30, 2024.
• The results are presented separately for the 'Successor' period (post-bankruptcy) and the 'Predecessor' period (pre-bankruptcy), making direct comparisons challenging due to fresh start accounting.
• Total net revenues for the Successor period were $284.2 million, while the Predecessor period from April 1, 2024, to April 23, 2024, reported $162.5 million, and the three months ended June 30, 2023, reported $546.9 million.
• The company reported a gross loss of $49.5 million for the Successor period, compared to a gross profit of $101.9 million for the Predecessor period from April 1, 2024, to April 23, 2024, and $313.0 million for the three months ended June 30, 2023.
• The Successor period's cost of revenues was significantly impacted by fresh start accounting, including $192 million related to inventory step-up amortization.
• The company reported a net loss of $148.8 million for the Successor period, compared to a net income of $6.5 billion for the Predecessor period from April 1, 2024, to April 23, 2024, and a net income of $23.4 million for the three months ended June 30, 2023.
• The company's total assets were $4.96 billion as of June 30, 2024, and total liabilities were $3.12 billion, resulting in a total shareholders equity of $1.83 billion.
• The company's total assets were $5.14 billion as of December 31, 2023, and total liabilities were $11.74 billion, resulting in a total shareholders deficit of $6.6 billion.
• The company's weighted average shares outstanding were 76.16 million for the Successor period, compared to 235.22 million for the Predecessor period from April 1, 2024, to April 23, 2024, and the three months ended June 30, 2023.
• The company's net loss per share was $1.95 for the Successor period, compared to a net income per share of $27.75 for the Predecessor period from April 1, 2024, to April 23, 2024, and a net income per share of $0.10 for the three months ended June 30, 2023.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company has successfully emerged from bankruptcy, the financial results are weak, with a significant net loss and negative gross margin. The company also faces numerous risks and uncertainties. The sentiment is therefore negative.

Positives

• The company successfully emerged from Chapter 11 bankruptcy, establishing a new capital structure.
• The company has a new board of directors and a new management team.
• The company has access to a $400 million revolving credit facility, which remains undrawn as of June 30, 2024.

Negatives

• The company reported a net loss of $148.8 million for the Successor period.
• The company's gross margin percentage was negative 17.4% for the Successor period, primarily due to fresh start accounting adjustments.
• The company's revenues decreased compared to the prior year, primarily due to competitive pressures in the Generic Pharmaceuticals segment and the impact of the prior year Novavax Settlement Agreement in the Sterile Injectables segment.

Risks

• The company's financial results are subject to significant risks and uncertainties, including competition, litigation, regulatory changes and economic conditions.
• The company's ability to fund its operations, maintain adequate liquidity and meet its financing obligations is reliant on its operations, which are subject to significant risks and uncertainties.
• The company's variable rate indebtedness exposes it to interest rate risk, which could cause debt costs to increase significantly.
• The company may not realize the anticipated benefits from its strategic actions.
• The company is subject to various laws, court orders and regulations pertaining to the marketing of its products and services.
• The company is subject to complex reporting and payment obligations under Medicaid and other governmental drug pricing programs.
• The company is subject to information privacy and data protection laws that include penalties for noncompliance.
• The company's ability to protect and maintain its proprietary and licensed technology is uncertain.
• The company may be subject to claims that were not discharged in the bankruptcy proceedings.
• The company may be subject to litigation in connection with the consummation of the Plan on the Effective Date.
• The company's ability to attract and retain key personnel following the consummation of the Plan is critical to the success of its business.
• The company has substantial indebtedness following consummation of the Plan which may adversely affect its financial position and operating flexibility.
• The settlement reached with the DOJ in resolution of its pre-bankruptcy criminal and civil investigations of certain Debtors may lead to further disciplinary action.
• Endo, Inc. could incur additional payment obligations pursuant to the U.S. Government Economic Settlement upon the achievement of certain EBITDA outperformance targets.
• The public trading price of the company's common stock may be volatile and could decline significantly and rapidly.
• An active, liquid and orderly market for the company's common stock may not develop or be sustained.
• The company does not intend to pay dividends on its common stock for the foreseeable future.
• Additional issuances of the company's common stock could result in significant dilution to its stockholders.
• Certain stockholders, if they choose to act together, will have the ability to control all matters submitted to stockholders for approval, including controlling the outcome of director elections.
• Anti-takeover provisions in the company's governing documents and under Delaware law could make an acquisition of the company more difficult, limit attempts by its stockholders to replace or remove its current management and depress the market price of its common stock.
• The company's governing documents also provide that the Delaware Court of Chancery is the sole and exclusive forum for substantially all disputes between the company and its stockholders and federal district courts are the sole and exclusive forum for Securities Act claims, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with the company or its directors, officers or employees.

Future Outlook

The company believes its principal sources of liquidity and cash on hand will be sufficient to meet its principal liquidity requirements for the next twelve months from the date of issuance of the Condensed Consolidated Financial Statements.

Management Comments

• The company's management, with the participation of the Company's Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, as of June 30, 2024.
• Based on that evaluation, the Company's Principal Executive Officer and Principal Financial Officer each concluded that the Company's disclosure controls and procedures were effective as of June 30, 2024.

Industry Context

The pharmaceutical industry is intensely competitive, and Endo Inc. faces competition in both its U.S. and international branded and generic pharmaceutical businesses. The company's financial results are also affected by regulatory changes, pricing pressures and the availability of third-party reimbursement for its products.

Comparison to Industry Standards

• The company's gross margin percentage of negative 17.4% for the Successor period is significantly below industry standards, primarily due to the impact of fresh start accounting.
• The company's net loss per share of $1.95 for the Successor period is significantly below the industry average, reflecting the impact of fresh start accounting and the company's ongoing restructuring.
• The company's revenue decline in the Generic Pharmaceuticals segment is consistent with industry trends of increased competition and pricing pressures.
• The company's reliance on third-party manufacturers is a common practice in the pharmaceutical industry, but it also exposes the company to supply chain risks.
• The company's focus on developing innovative and clinically differentiated product candidates is consistent with industry trends of investing in R&D to maintain a competitive edge.

Management Changes

Legal Proceedings

• Endo, Inc. and certain of its subsidiaries as well as Endo International plc and certain of its subsidiaries, including certain Debtors, are involved in various claims, legal proceedings and internal and governmental investigations arising from time to time, including, among others, those relating to product liability, intellectual property, regulatory compliance, consumer protection, tax and commercial matters.
• An adverse outcome in certain proceedings described herein could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Stakeholder Impact

• Shareholders may experience volatility in the trading price of the company's common stock.
• Employees may be affected by potential organizational changes and the company's focus on operational efficiency.
• Customers may be affected by changes in product availability and pricing.
• Suppliers may be affected by changes in the company's supply chain and manufacturing operations.
• Creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company will continue to focus on its strategic priorities, including product development, commercialization and operational efficiency.
• The company will continue to monitor and manage its financial obligations and liquidity.
• The company will continue to evaluate and pursue opportunities to enhance its product line and business operations.

Key Dates

Keywords

Endo Inc., Chapter 11, bankruptcy, financial results, pharmaceuticals, reorganization, fresh start accounting, opioids, litigation, generic drugs, branded drugs, Sterile Injectables